Caitlin Kontulis serves as Executive at RXi Pharmaceuticals Corp, where they oversee executive responsibilities. Since joining the company, Caitlin Kontulis has executed 13 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Mar 1, 2024 involved selling 335 shares valued at $322.
Caitlin Kontulis currently holds 10,643 shares of RXi Pharmaceuticals Corp (RXII), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Caitlin Kontulis has been a net neutral trader of RXII stock. They have purchased $0 and sold $0 worth of shares.
Caitlin Kontulis's most recent insider trade was on Mar 1, 2024, when they sold 335 shares at $0.96 per share.
Get notified when new Form 4 filings are submitted
| $0.66 |
| Discretionary |
| Feb 15, 2024 | PHIO | $428 | Payment | 658 | $0.65 | Discretionary |
| Mar 1, 2023 | PHIO | $1.8K | Payment | 335 | $5.49 | Discretionary |
| Feb 17, 2023 | PHIO | $0 | Award | 4,500 | $N/A | Discretionary |
| Feb 15, 2023 | PHIO | $3.4K | Payment | 657 | $5.20 | Discretionary |
| Mar 1, 2022 | PHIO | $3.3K | Payment | 4,011 | $0.82 | Discretionary |
| Feb 15, 2022 | PHIO | $0 | Award | 68,000 | $N/A | Discretionary |
| Mar 1, 2021 | PHIO | $0 | Award | 34,600 | $N/A | Discretionary |
| Nov 18, 2019 | PHIO | $23.8K | Award | 237,500 | $0.10 | Discretionary |
| Aug 1, 2019 | PHIO | $300 | Payment | 749 | $0.40 | Discretionary |
| Feb 13, 2019 | PHIO | $0 | Award | 27,000 | $N/A | Discretionary |
| Aug 1, 2018 | RXII | $0 | Award | 10,500 | $N/A | Discretionary |